Core Viewpoint - Long-term institutional investors are revealing their positions amidst short-term market fluctuations, indicating a deeper judgment on future market trends by renowned fund managers like Zhang Kun and Ge Lan [2][18]. Group 1: Zhang Kun's Portfolio Adjustments - Zhang Kun's management of the E Fund Blue Chip Select has seen a slight reduction in stock positions, with the stock holding ratio decreasing from 94.14% to 92.63%, marking the lowest level in nearly three years [3]. - The fund's top ten holdings now account for 83.84% of its net value, the highest in the past ten quarters, while the "invisible heavyweights" (ranked 11th to 20th) have significantly decreased from 18.05% to 9.22% [3][4]. - Notable adjustments include a reduction in holdings of Meituan-W by 46.43% and an increase in holdings of Fenzhong Media from 1.53 million shares to 2.48 million shares [4][5]. Group 2: Ge Lan's Focus on Innovative Pharmaceuticals - Ge Lan's management of the China Europe Fund has seen a significant increase in the number of holdings in innovative pharmaceuticals, with the top ten holdings including new entries like Xinli Tai and Bai Li Tian Heng [10][12]. - The fund's turnover rate reached 61.3%, indicating a dynamic adjustment strategy, with a notable increase in the number of innovative drug stocks in the top twenty holdings [10][12]. - Ge Lan emphasizes that the pharmaceutical sector will continue to grow driven by innovation, consumer recovery, and domestic substitution, with a focus on the innovative drug industry chain and consumer healthcare [19][20]. Group 3: Market Sentiment and Future Outlook - Zhang Kun challenges the prevailing pessimistic view on domestic demand, arguing that consumer confidence is influenced by expectations rather than just current economic conditions [18][19]. - Ge Lan anticipates that the pharmaceutical industry will rely on innovation breakthroughs and consumer recovery for growth, despite potential risks from global economic fluctuations [19][20].

Core Viewpoint - FTSE Russell announced quarterly review changes for multiple indices, effective after the close on September 19, 2025, with significant implications for the FTSE China A50 Index [2][5]. Group 1: Index Changes - The FTSE China A50 Index will include stocks such as BeiGene-U, NewEase, WuXi AppTec, and Zhongji Xuchuang, which are primarily from the pharmaceutical and AI computing sectors [3][6]. - Stocks removed from the FTSE China A50 Index include China Nuclear Power, China Unicom, Guodian Nari, and Wanhua Chemical [6][7]. - The FTSE China A50 Index consists of the 50 largest stocks listed on the Shanghai and Shenzhen exchanges, reviewed quarterly [7]. Group 2: Stock Performance - BeiGene-U has doubled in value this year, with a growth rate of 102.51%, and a market capitalization of approximately 466.4 billion [7]. - WuXi AppTec also experienced a doubling in its stock price, while NewEase surged over three times, and Zhongji Xuchuang increased by over 240%, with a market cap exceeding 470 billion [7]. Group 3: Market Trends - The inclusion of stocks in the FTSE Russell indices often leads to significant buying pressure from index-tracking funds, particularly around the effective date of the changes [8]. - The AI computing sector is expected to see explosive growth in demand as it plays a crucial role in the AI industry, impacting various segments of the supply chain [11]. - The pharmaceutical sector is experiencing a shift towards innovation-driven growth, with a focus on value creation through new drug models, which is anticipated to result in greater market capitalization increases compared to previous cycles [11].

Core Insights - The total margin balance of the STAR Market on September 3 was 228.939 billion yuan, a decrease of 1.9 billion yuan from the previous trading day [1] - The financing balance was 228.159 billion yuan, down by 1.892 billion yuan, while the securities lending balance was 0.78 billion yuan, a decrease of 0.08 billion yuan [1] Individual Stock Performance - On September 3, 258 stocks in the STAR Market experienced net financing inflows, with 10 stocks having net inflows exceeding 30 million yuan [1] - Dongxin Technology topped the list with a net financing inflow of 263 million yuan, followed by Baiji Shenzhou, Airo Energy, Yuanjie Technology, and Shijia Photon, all with net inflows exceeding 50 million yuan [1]

Group 1 - The financing balance of the Sci-Tech Innovation Board decreased by 1.89 billion yuan compared to the previous day, with a total margin balance of 228.94 billion yuan as of September 3 [1][2] - Among the stocks, 51 had a financing balance increase of over 10 million yuan, with notable net purchases in Dongxin Co., BeiGene, and Airo Energy [1][2] - The stocks with financing balances exceeding 1 billion yuan totaled 473, with 32 stocks having balances over 1 billion yuan [1] Group 2 - Dongxin Co. had the highest net purchase amount, with a financing balance of 2.691 billion yuan, an increase of 263.42 million yuan, and a daily increase of 1.17% [2][3] - The average increase in stocks with net purchases exceeding 10 million yuan was 1.23%, with the highest increases seen in Haibo Sichuang, Airo Energy, and Chengdu Huamei, which rose by 20.00%, 19.15%, and 14.97% respectively [2][3] - The electronic, pharmaceutical, and power equipment sectors were the most favored by investors, with 13, 10, and 10 stocks respectively [2] Group 3 - The average financing balance as a percentage of market capitalization for stocks with significant net purchases was 4.16%, with the highest ratio seen in Zhongyan Co. at 13.44% [2][3] - Other stocks with high financing balance ratios included Yitang Co., Rongbai Technology, and Youfang Technology, with ratios of 10.00%, 8.09%, and 7.97% respectively [2][3] - The stocks with the largest financing balance decreases included SMIC, Cambrian, and Lanke Technology, with decreases of 305 million yuan, 218 million yuan, and 165 million yuan respectively [1][2]

9月3日，富时罗素宣布对富时中国50指数、富时中国A50指数等的季度审核变更，纳入百济神州、药明 康德等A股，剔除中国核电等A股。该变更将于2025年9月19日星期五收盘后（即9月22日星期一）生 效。 点评：作为全球知名的指数编制公司，富时罗素的纳入标准较为严格，此次调整体现了A股公司在全球 资本市场中的重要性不断提升，以及外资对中国创新药板块的持续关注和参与。 NO.3 大冢制药IgA肾病靶向药物上市申请获受理 每经记者｜林姿辰 每经编辑｜张益铭 丨2025年9月4日 星期四丨 NO.1 永安药业实际控制人、董事长解除留置 9月3日，永安药业发布公告称，公司收到实际控制人、董事长陈勇家属的通知，其收到鹤峰县监察委员 会出具的《解除留置通知书》，鹤峰县监察委员会已解除对陈勇先生的留置措施。目前，陈勇已能正常 履行公司董事长的职责，公司生产经营情况正常。 点评：在资本市场，公司管理层的稳定性是投资者关注的关键因素之一，尤其董事长作为核心人物，其 解除留置并恢复正常履职，消除了此前因留置措施带来的不确定性，有助于增强投资者对公司未来发展 的信心。 NO.2 富时中国A50指数纳入百济神州等A股 点评：本事件将拓 ...

Group 1 - FTSE Russell announced quarterly adjustments to several indices, including the FTSE China A50 Index, which will take effect after the market closes on September 19, 2025 [2] - The FTSE China A50 Index will include new stocks: BeiGene, NewEase, WuXi AppTec, and Zhongji Innolight, while excluding China National Nuclear Power, China United Network Communications, NARI Technology Development, and Wanhua Chemical Group [2][3] - The adjustments reflect market trends, with the newly included companies aligning with recent hot sectors, particularly in innovative pharmaceuticals and AI optical modules [4] Group 2 - BeiGene and WuXi AppTec are leaders in the innovative drug sector, with BeiGene's stock reaching a historical high of 346 CNY per share on September 2, 2023, and a year-to-date increase of 102.51% [4] - The AI optical module companies, NewEase and Zhongji Innolight, have seen significant stock performance, with Zhongji Innolight's stock price at 426.19 CNY per share and a year-to-date increase of 246.45% [4] - Financial results for the first half of the year show substantial growth for both AI leaders, with Zhongji Innolight reporting revenue of 14.789 billion CNY (up 36.95%) and net profit of 3.995 billion CNY (up 69.4%), while NewEase reported revenue of 10.437 billion CNY (up 282.64%) and net profit of 3.942 billion CNY (up 355.68%) [5]

Core Insights - FTSE Russell announced quarterly review changes for several indices including FTSE China 50 Index, FTSE China A50 Index, FTSE China A150 Index, FTSE China A200 Index, and FTSE China A400 Index, effective after market close on September 19, 2025 [1] - The most notable change is the inclusion of four stocks in the FTSE China A50 Index: BeiGene Ltd (百济神州-U), Xinyisheng (新易盛), WuXi AppTec (药明康德), and Zhongji Xuchuang (中际旭创), while excluding China National Nuclear Power, China Unicom, GD Power Development, and Wanhua Chemical [1] - According to Wind statistics, the newly included stocks have all seen significant price increases, with gains exceeding 100% year-to-date as of September 3, 2023 [1][2] Stock Performance - Xinyisheng (新易盛) has increased by 349.64% year-to-date [2] - Zhongji Xuchuang (中际旭创) has increased by 246.45% year-to-date [2] - WuXi AppTec (药明康德) has increased by 105.82% year-to-date [2] - BeiGene Ltd (百济神州-U) has increased by 102.51% year-to-date [2] Backup Stocks - The backup stock list for the FTSE China A50 Index includes Minsheng Bank, Luoyang Molybdenum, Tonghuashun, SAIC Motor, and Seres [2] - These backup stocks will be considered for inclusion if any of the current constituents are removed before the next quarterly review [2]

Group 1 - FTSE Russell announced changes to the FTSE China 50 Index, FTSE China A50 Index, FTSE China A150 Index, FTSE China A200 Index, and FTSE China A400 Index, with the most notable inclusion being BeiGene, NewEase, WuXi AppTec, and Zhongji Innolight, while excluding China National Nuclear Power, China United Network Communications, NARI Technology Development, and Wanhua Chemical Group [2][4] - The changes will take effect after the market closes on September 19, 2023, and will officially be implemented on September 22, 2023 [2] - Zhongji Innolight's stock price surged approximately 11% on September 3, reaching a historical high with a market capitalization exceeding 470 billion yuan, ranking second on the ChiNext board [7] Group 2 - The newly included companies in the FTSE China A50 Index are primarily from the innovative drug and optical module sectors, which have shown significant stock price increases this year [4] - The FTSE China A50 Index's reserve list includes Minsheng Bank, CMOC Group, Hithink RoyalFlush Information Network, SAIC Motor, and Seres Group, which may be activated if any of the current constituents are removed before the next quarterly review [7][8]

Core Viewpoint - FTSE Russell announced changes to the FTSE China 50 Index, FTSE China A50 Index, FTSE China A150 Index, FTSE China A200 Index, and FTSE China A400 Index, with the most notable changes occurring in the FTSE China A50 Index, which will include new companies and exclude others starting September 22, 2023 [1][3]. Group 1: Index Changes - The FTSE China A50 Index will include BeiGene Ltd (百济神州-U), Eoptolink Technology (新易盛), WuXi AppTec (药明康德), and Zhongji Innolight (中际旭创) [1][3]. - The index will exclude China National Nuclear Power (中国核电), China United Network Communications (中国联通), NARI Technology Development (国电南瑞), and Wanhua Chemical Group (万华化学) [1][3][4]. Group 2: Market Impact - Companies added to the FTSE China A50 Index are expected to attract more passive fund inflows, which could positively impact their stock prices [5]. - Zhongji Innolight's stock price increased by approximately 11% on September 3, reaching a historical high with a market capitalization exceeding 470 billion yuan, making it the second-largest company on the ChiNext board [4]. - From August 1 to September 3, Zhongji Innolight's stock price surged over 95% [4]. Group 3: Backup List - The backup list for potential replacements in the FTSE China A50 Index includes Minsheng Bank, Luoyang Molybdenum, Tonghuashun, SAIC Motor, and Seres [5].

Group 1 - Goldman Sachs remains optimistic about the Chinese stock market, indicating that investor sentiment has significantly improved and there is still room for growth [1] - The Shanghai Gold Exchange has adjusted margin levels and price fluctuation limits for gold and silver contracts, effective from September 5, 2025 [2] - FTSE Russell announced changes to the FTSE China A50 Index, including the addition of four stocks such as BeiGene and the removal of four others [3] Group 2 - Renowned analyst Ming-Chi Kuo has raised Apple's foldable iPhone shipment forecasts for 2026 and 2027, reflecting strong expectations for the new product [4] - The Ministry of Finance and the People's Bank of China emphasize the importance of coordinated fiscal and monetary policies to support economic recovery [5] - The semiconductor industry is set to gain attention with the upcoming CSEAC 2025 exhibition, as analysts predict a new growth phase driven by AI demand and inventory adjustments [15] Group 3 - The automotive sector is receiving additional budget support from Chongqing for vehicle replacement subsidies [16] - The new energy vehicle market in China saw a retail year-on-year growth of 5% in August, indicating a positive trend [17] - Major paper manufacturers have announced price increases for certain products, reflecting market dynamics [17] Group 4 - GoerTek has established a new technology company that includes smart robotics as part of its business expansion [18] - Robotech signed a significant contract worth approximately €946.5 million for automated silicon photonic packaging equipment [22] - Wild Horse Battery's shareholders plan to reduce their holdings by up to 3%, indicating potential changes in ownership structure [22]